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 Frequent medication errors have been observed in adult populations using inhaled 
asthma controller medications for respiratory diseases including asthma and COPD. These errors 
are associated with higher rate of exacerbations and decreased patient outcomes. Little research 
has been reported demonstrating medication errors in the adolescent asthma population. This 
study aims to bridge the gap in literature, demonstrating the number and types of errors 
adolescents and caregivers report regarding adolescent use of asthma controller medications.  
Methods: 
 Forty-six providers from four pediatric primary care practices in North Carolina 
participated in the study. Adolescents that met inclusion criteria were interviewed about their 
asthma controller medication use while caregivers were asked to compete a written questionnaire 
reporting knowledge of their adolescent’s medication use. Inclusion criteria included: ages 11 to 
17 years old, spoke and read English or Spanish, had persistent asthma, were present for an acute 
or follow-up asthma visit or a well-child visit, and had previously visited the clinic at least once 
for asthma. Answers reported by adolescents and caregivers were compared to the prescribed 
administration instructions in the adolescent’s medical record. Discrepancies between reported 
use and prescribed instructions outlined in the adolescent’s medical record were defined as an 
error. Descriptive and regression statistical analysis was applied to the dataset using IBM SPSS 
Statistics software. 
Results:  
Three hundred and nineteen adolescents participated in the study. Thirty-eight percent of 
adolescents reported one error using asthma controller medications. Sixteen percent reported two 
errors and 5% reported three or more errors. Forty-two percent of caregivers reported one error 
in adolescents using asthma controller medications. Fourteen percent reported two errors, while 
6% reported three or more errors. The type of error most frequently reported by both adolescents 
and caregivers was not taking the medication at all, reported by 32% of adolescents and 29% of 
caregivers. The medication associated with the most reported errors was QVAR, reported by 
32% of adolescents and 31% of caregivers. 
Conclusions:  
Both adolescents and caregivers commonly report errors in adolescent use of asthma 
controller medication. Providers and pharmacists can work to educate adolescent patients on 
asthma controller medication use to prevent medication errors.  
Introduction 
An estimated 6 million children are diagnosed with asthma, making it one of the most 
common chronic illnesses among adolescents.1 Asthma is characterized by chronic airway 
inflammation, leading to airflow obstruction and bronchial hyperresponsiveness.2 This causes 
clinical symptoms including shortness of breath, chest tightness, coughing, wheezing, and 
difficulty breathing.2 These asthma symptoms can have a large impact on the adolescent’s 
quality of life by limiting school, social and physical activities.3 Management of this chronic 
illness often requires repeated physician visits and is associated with increased emergency 
department visits.4 Standard of care for patients with persistent asthma includes long term control 
medications that reduce airway inflammation, relieve symptoms and prevent exacerbations.3,5 
According to the National Heart, Lung, and Blood Institute asthma practice guidelines, the 
preferred treatment for persistent asthma consists of low dose inhaled corticosteroids (ICS), with 
step up therapy increasing ICS dose or adding additional agents (long acting beta agonist, 
montelukast, or oral corticosteroids). Oral tablets including cromolyn or montelukast can be used 
as alternative treatment.1,5  
 Caregiver involvement has been studied in adolescent populations, with increased 
involvement associated with better patient outcomes.6 Excessive self-care autonomy at 
inappropriate ages of adolescent patients has also been associated with decreased medication 
adherence in the adolescent population.7 This work has been translated directly to the adolescent 
asthma population, with increased ED visits in adolescents with caregivers suffering from 
psychological health illnesses such as depression.8 By analyzing both adolescent self-reported 
medication use and caregiver reporting, this study aims to provide more depth on caregiver 
involvement in adolescent asthma management.  
Medication errors can be defined as preventable events that lead to inappropriate 
medication use.9 These errors are highly prevalent among the adolescent population in a variety 
of medication classes.10,11 Previous research focuses on over-the-counter acetaminophen and 
chemotherapy medication, leading to toxicity and hospitalization of this population.10-14 
However, little research has been performed regarding the types of errors that adolescents make 
in using asthma controller medications. 
 Previous research has studied the misuse of inhalers in the adult COPD and asthma 
populations. A cross-sectional study analyzing errors in the outpatient respiratory care setting 
found at least one incorrect step in 48.2% of patient inhalation demonstrations while using 
COPD controller inhalers.15 Melani, et al. analyzed medication errors associated with controller 
inhalers in both adult COPD and asthma populations, finding errors in metered dose inhalers 
(MDI), dry powder inhalers (DPI), and Turbohalers (12%, 35%, and 44%, respectively).16 A 
study in the European Respiratory Journal found similar results in the adult COPD population, 
with < 40% of patients able to perform appropriate inhalation technique compared to package 
insert instructions leading to increased exacerbations in past 3 months.17 Despite the extensive 
body of research reporting medication errors in the adult asthma and COPD population, there is a 
lack of evidence in medication errors in regard to the pediatric asthma population. This study 
aims to bridge the gap in literature and determine the number and types of medication errors in 
the adolescent asthma population. 
Methods 
Study Population 
 Forty-six providers from four pediatric primary care practices in North Carolina agreed to 
participate in the study. The primary care practices included one academic practice and three 
private practices. The principal investigator visited each clinic to obtain written provider consent. 
Participants in the study were enrolled from June 2015 to November 2016. Staff from each 
practice explained the study to families attending the primary care practice for asthma 
management in adolescent patients. Families interested in the study were then referred to a 
research assistant to learn more. Research assistants explained the study to families during the 
pre-visit wait time where they obtained adolescent assent and caregiver consent and completed 
HIPAA forms. Research assistants then administered eligibility screeners for the study.  
Adolescents were eligible if they met the following inclusion criteria: ages 11 to 17 years 
old, spoke and read English or Spanish, had persistent asthma, were present for an acute or 
follow-up asthma visit or a well-child visit, and had previously visited the clinic at least once for 
asthma. Persistent asthma was defined using the National Health Lung and Blood Institute 
Guidelines – experiencing asthma-related daytime symptoms more than twice a week, asthma-
related nighttime symptoms more than twice a month or receiving one or more long-term 
controller therapies for asthma.1 Caregivers were eligible if they were greater than 18 years of 
age, spoke and read English or Spanish, and were legal guardian of the adolescent. 
Four hundred and sixty-nine adolescents were initially screened for study inclusion. Out 
of these 469, 319 were on controller medications reported in their medical records and met 
inclusion criteria. Controller asthma medications included: Montelukast, QVAR Redihaler, 
ProAir HFA, Proventil HFA, Ventolin HFA, Advair, Symbicort, Xopenex HFA, and 
Pulmicort Flexhaler. Adolescents and caregivers were both provided $25 for their time. 
Adolescent and Caregiver Reported Errors  
Adolescents were interviewed for the study after meeting with their primary care 
provider. In the interview, adolescents were asked the following questions regarding the use of 
their asthma controller medications: 
• Medication name?  
• How many days did you (adolescent) use it in the past week?  
• How many times per day did you (adolescent) use it?  
• How many pills or puffs did you (adolescent) use each time?  
• How many times did you (adolescent) miss taking it?  
• How well does the medicine work for you (adolescent)?  
Caregivers were asked to complete a written questionnaire with the same questions 
regarding their adolescent’s medication use stated above. Information from the adolescent 
interviews and caregiver questionnaire was extracted and compared to the adolescent’s medical 
record. Medication errors were defined by analyzing discrepancies in reported adolescent use 
compared to prescribed medication administration instructions (Table 2).  
 
Medical Record Extraction 
 Each adolescent’s medical record had information abstracted by the research assistant 
twelve months before the baseline visit. Information extracted from the medical record included 
the intended administration schedule of each prescribed asthma controller medication. All 
medications prescribed for asthma control use were extracted and included in the study. Any 
additional medication not prescribed for asthma diagnosis was omitted. Adolescent age was 
extracted from the medical record. 
Patient Sociodemographic Factors 
Caregivers were asked a variety of questions regarding sociodemographic factors of the 
adolescent, caregiver and household, including primary language spoken at home, race, total 
annual household income, and adolescent’s health insurance type. 
Adolescent age was extracted from medical record and measured as continuous variable. 
Adolescent and caregiver gender was measured as dichotomous variable. Languages spoken at 
home were measured as a dichotomous variable (English or Spanish). Adolescent race/ethnicity 
was organized as five categories: white, African American, native American/American Indian, 
Hispanic, other. Caregiver race was measured by dichotomous variable (white or non-white). 
Total self-reported household alumni was categorized into 6 categories: less than $10,000, 
$10,000-$19,999, $20,000-$29,999, $30,000-$49,999, $50,000-$69,999 and $70,000 or more. 
Type of health insurance was measured as dichotomous variable (Medicaid or other). Asthma 
severity was measured as dichotomous variable, classified as mild persistent vs moderate/severe 




 All analyses were conducted using IBM SPSS Statistics. Descriptive statistics were 
computed for the number and types of errors that were reported by both adolescents and 
caregivers. Descriptive statistics were computed for the adolescent and caregiver 
sociodemographic characteristics were imported from an existing dataset. Multivariable 
regression was utilized to predict whether sociodemographic factors were associated with 
adolescents and caregivers reporting one or more errors in using asthma controller medication. 
Results 
Table 1 demonstrates the youth and caregiver demographic characteristics. Fifty-seven of 
patients were male. The average adolescent age was 13.2 years old (SD 1.9) and ranged from 11 
to 17 years old. Thirty-six percent of adolescents were Caucasian, 37.2% African American, 
13% Hispanic, 11% Native American. Ninety-one percent of adolescents reported English as 
their primary language at home, while nine percent reported Spanish.  
Table 2 demonstrates the typology of errors created comparing reported use to 
administration instructions as prescribed in the adolescent’s medical record. Errors included: 
extra single administration doses, too few single administration doses, taking too frequently per 
day, not taking enough times per day, missing 1-3 doses per week, missing 3+ doses per week, 
not taking at all, or does not know names of all medication. 
Table 3 demonstrates the number of errors detected for adolescents and caregivers by 
comparing their reported medication use to the medication directions in the medical record. 
Many errors were detected for both adolescents and caregivers, 58% and 61% respectively. 
Thirty-eight percent of adolescents reported one error, 16% reported two errors, 5% reported 
three or more errors. Forty-two percent of caregivers reported one error, 14% reported two 
errors, 6% reported three or more errors.  
Table 4 demonstrates the types of errors reported by adolescents and caregivers. The 
three most commonly reported errors by adolescents were not making the medication at all, 
missing three or more doses per week, and not taking the medication enough times per day. 
Thirty-two percent of adolescents reported not taking the medication at all. Fifteen percent of 
adolescents reported missing three or more doses per week. Ten percent of patients reported not 
taking the medication enough times per day. The three most commonly reported errors by 
caregivers were not taking the medication at all, missing three or more doses per week, and 
missing 1-3 doses per week. Twenty-nine percent of caregivers reported the adolescent not 
taking the medication at all. Fourteen percent of caregivers reported missing three or more doses 
per week. Nine percent of caregivers reported missing 1-3 doses per week. The most commonly 
reported errors for both adolescents and caregivers was not taking the medication at all and 
missing three or more doses per week. The least commonly reported for both adolescents and 
caregivers was taking doses too frequently per day, 4% and 3% respectively.  
Table 5 demonstrates the number of errors associated with each type of controller 
medication. Thirty-two percent of adolescents reported errors associated with QVAR 
Redihaler, use, the highest amount across each type of controller medications. Thirteen percent 
reported errors with Flovent HFA, while 12% of adolescents reported errors with Montelukast. 
The three medications with the highest number of errors reported by caregivers were QVAR 




 Caregivers were more likely to report errors than adolescents (61.4% caregivers vs 58% 
adolescents). When adolescents and caregivers do report errors, the most common reported error 
across both groups is not taking the medication at all. The second most commonly reported 
errors was missing three or more doses per week. No significant discrepancies in medication 
error reporting was observed between adolescent and caregiver answers. These findings 
demonstrate that although slight deviations may occur, adolescents and caregivers are generally 
consistent in their involvement in the adolescent’s asthma controller medication use. Both 
caregivers and adolescents reported the most medication errors with QVAR Redihaler, (32% 
adolescents, 31% caregivers) with Flovent being second medication with the most errors (13% 
adolescents, 13% caregivers). 
 Previous research has analyzed medication errors in the adolescent cancer population. 
Walsh et al., reported 17% of patients reported non-adherence in the adolescent population, 
while 13% of patients reported missing doses in the last 7 days for any medicine used in the 
cancer treatment, both chemotherapy and supportive meds.10  Similar to asthma controller 
medication, chemotherapy and supportive meds may have difficult administration techniques and 
instructions for adolescents. This creates opportunity for both adolescents and caregivers to 
misinterpret appropriate administration schedule and/or instructions, leading to errors in the 
population. Our study found similar information in regard to the errors that were reported. 
Medications that had strict administration schedule had more errors reported than as needed 
medication.  
 Another clinical area that has research regarding the number and types of errors that are 
performed is over the counter medications. Due to high availability and use in the adolescent 
population, these medications are associated with high risks of medication errors. Alander et al., 
studied medication errors in regard to over-the-counter acetaminophen. In this study, 3% of 
errors were identified as unintentional dosing errors due to either excess medication self-
medicated by the adolescent or provided unintentionally by the caregiver.13 We found that both 
adolescents and caregivers were likely to report medication errors when using the medication, 
demonstrating the clinical need for both adolescent patients and caregivers to be educated in 
regard to correct medication use.  
There is a current gap in knowledge regarding misuse of medications in the adolescent 
population, particularly in using asthma controller medications. The results of this study can be 
used to improve the communication between physicians and patients regarding using asthma 
controller medications. By learning the types of errors that adolescents and caregivers make, 
physicians can address relevant concerns in follow up visits regarding chronic asthma 
management. Physicians can utilize this information to ensure that both adolescent patients and 
caregivers are appropriately educated on asthma controller medications in order to decrease 
unnecessary follow up visits and improve patient outcomes.   
The pharmacist’s role in healthcare includes providing patients with information to take 
their medications appropriately. Utilizing this information, pharmacists in the community setting 
will be able to cater their patient education in order to maximize patient care in the adolescent 
asthma population. Emphasizing the importance of adherence in the adolescent patient 
population while using scheduled controller medication can decrease need for rescue inhalers.  
There are various limitations that exist within this study. One limitation is that providers 
may not accurately report how patients should be using the medication in the medical record or 
may not update the medical record as instructions change for the patient over time. This may 
falsely increase the number of errors reported when comparing patient use to an incorrect 
medical record. The patients included in this study were attending pediatric clinics instead of 
specifically pulmonology clinics, which may have limited generalizability to those with severe 
asthma diagnosis. The patients in this study were only in North Carolina, which may not be 
representative of the entire U.S. adolescent population. The adolescent and caregiver reports may 
not assess all types of errors (incorrect spacer use, incorrect inhalation technique, etc) which is a 
limitation in our study. Despite the limitations, the study plays a key role in improve the 
communication that both physicians and pharmacists have with adolescents in regard to their 
asthma controller medications.  
Future research can be performed to assess provider and pharmacist interventions in 
reducing the amount of medication errors adolescents report regarding asthma controller use. A 
future study idea is to analyze number and types of errors reported before and after pharmacist 
counseling interventions on the adolescent asthma population. This analysis may can the impact 
of community pharmacists to reduce the amount of medication errors this patient population. 
Providers can utilize this information when establishing routine care with pediatric asthma 
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Table 1: Youth and caregiver demographic and youth asthma-related characteristics (N=359) 
 
Characteristics Percent (N)  
  
Youth Gender  
Male 57.1 (205) 
Female 42.9 (154) 
Youth Race/Ethnicity  
Caucasian 36.2 (130) 
African American 37.2 (134) 
Hispanic 12.5 (45) 
Native American 11.4 (41) 
Other   2.5 (9) 
Asthma Severity  
Mild 46.8 (168) 
Moderate/Severe 53.2 (191) 
Caregiver Gender  
Male 13.6 (49) 
Female 86.4 (310) 
Caregiver Race  
Caucasian 46.0 (165) 
Non-Caucasian 54.0 (194) 
On Controller Medication  
Yes 88.9 (319) 
No 11.1 (40) 
Primary Language Spoken at Home  
English 91.5 (292) 
Spanish   8.5 (27) 
Reason For Visit  
Asthma 66.6 (239) 
Other 33.4 (12) 
Household Total Annual Income  
Less than $10,000 16.4 (59) 
$10,000-$19,999 15.3 (55) 
$20,000-$29,999 18.7 (67) 
$30,000-$49,999 13.1 (47) 
$50,000-$69,999 13.1 (47) 
$70,000 or more 23.4 (84)_ 
Has Medicaid as Health Insurance  
Yes 54.6 (196) 
No 45.4 (163) 
 Mean (SD), Range 
Youth Age 13.2 (1.9), 11-17 
Years Living with Asthma 9.5 (4.1), 1-17 
Caregiver Age 42.6 (8.6), 19-76 








Table 2: Typology of Errors  
 
Type of Error  Error Definition 
Extra single administration doses Two puffs (or more) instead of one puff per 
administration 
Too few single administration doses One puff instead of two puffs per administration 
Taking too frequently per day Twice daily (or more) administration instead of 
prescribed once daily administration  
Not taking enough times per day Once daily administration instead of prescribed twice 
daily administration 
Missing 1-3 doses per week Missing less than three doses in a seven-day period 
Missing three or more doses per week Missing more than three doses in a seven-day period 
Not taking at all Does not report taking medication although listed on 
medical record 
Does not know names of all medication Reports medication with descriptive factors instead of 
name (i.e red inhaler, tablet, etc) 
 
 
Table 3: Number of Errors Reported by Adolescents and Caregivers (N=319) 
 
Reported Errors Adolescents Reporting Errors 
Percent (N = 319) 
Caregivers Reporting Errors 
Percent (N = 319) 
0 42.0 (134) 38.6 (123) 
1 37.6 (120) 41.7 (133) 
2 157.7 (50) 13.5 (43) 






Table 4: Types of Errors Reported by Adolescents and Caregivers (N=319) 
 
Error Type Adolescent Reporting Errors: 
Percent (N) 
Caregiver Reporting Errors 
Percent: Percent (N) 
Not Taking At All 31.9 (102) 28.8 (92) 
Missing 3+ Doses Per Week 15.4 (49) 14.4 (46) 
Not Taking Enough Times Per Day 9.40 (30) 7.52 (24) 
Missing 1-3 Doses Per Week 8.77 (28) 9.09 (29) 
Does Not Know Names of All 
Medication 
8.77 (28) 6.58 (21) 
Too Few Single Administration 
Doses 
3.76 (12) 5.64 (18) 
Extra Single Administration Doses 3.13 (10) 4.07 (13) 









Table 5: Number of Errors Reported for Each Controller Medication (N=319) 
 
 Adolescent Reported Errors 
Percent (N) 
Caregiver Reported Errors 
Percent (N) 
QVAR RediHaler 32.3 (103) 30.7 (98) 
Flovent HFA 12.5 (40) 12.5 (40) 
Montelukast 12.2 (39) 9.7 (31) 
Advair 11.9 (38) 11.0 (35) 
Proair HFA 2.8 (9) 2.8 (9) 
Ventolin HFA 1.9 (6) 2.8 (9) 
Pulmicort Flexhaler 1.3 (4) 0.9 (3) 
Proventil HFA 0.6 (2) 0.6 (2) 
Symbicort 0.6 (2) 0.3 (1) 
Xopenex HFA 0.3 (1) 0 (0) 
 
 
 
 
 
 
